

Please replace pages 22, 23, 26, and 28 with substitute sheets 22, 22/A, 23, 26, and 28 attached hereto. The substitute sheets include the identical text of the original pages, but with clear versions of Tables 1-4. The original specification included Tables which were difficult to read. Applicants have substituted clear versions of the same tables containing the identical information.

Please amend the first complete paragraph on page 1 of the specification under the heading Related Application to read as follows:

Related Application

910 This application is a divisional of U.S. Serial No. 08/960,774, filed October 30, 1997, now issued as U.S. Patent No. 6,239,116B1 on May 29, 2001, which is a continuation-in-part of U.S. Serial No. 08/738,652, filed October 30, 1996, which is now issued as U.S. Patent No. 6,207,646B1 on March 27, 2001, which is a continuation-in-part of U.S. patent application serial number 08/386,063, filed February 7, 1995 now issued as U.S. Patent No. 6,194,388B1 on February 27, 2001, which is a continuation-in-part of U.S. Patent Application 08/276,358, filed July 15, 1994 which is now abandoned, each of which are incorporated herein by reference in their entirety.

Please substitute replacement pages 38 and 47 filed with the response of March 7, 2001 with the attached replacement pages 38, 38/A, 47, and 47/A.

In the Claims:

Please rewrite the claims as shown.

DI 142. (Twice Amended) A method for increasing the responsiveness of a cancer cell to a cancer therapy using an immunostimulatory nucleic acid as compared to the absence of the immunostimulatory nucleic acid, comprising:

administering to a subject having a cancer an effective amount for increasing the responsiveness of a cancer cell to a cancer therapy of an immunostimulatory nucleic acid, comprising:



wherein C is unmethylated, wherein X_1X_2 and X_3X_4 are nucleotides, and wherein the sequence is not palindromic.